Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00157950
Status:
COMPLETED
Last Update Posted:
2016-02-04
First Post:
2005-09-07
Brief Title:
Human Papillomavirus HPV Registration Study GardasilV501-023COMPLETED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
An Immunogenicity and Safety Study of Gardasil V501 Human Papillomavirus Types 6 11 16 18 Recombinant Vaccine in Females 9 to 23 Years of Age in Korea
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an immunogenicity and safety study of Gardasil V501 in females 9 to 23 years of age in Korea
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_066 | None | None | None |